Physician profile
Glorimar Santos
NPI 1326144361
$2,345.94
in general payments reported to CMS, 2019-2025
11 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $241 · 2021: $129 · 2022: $405 · 2023: $178 · 2024: $398 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.03 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $661.97 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $463.48 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $329.88 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $134.51 | 2019-2022 | |
| Genzyme Corporation | $121.20 | 2022-2024 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $73.37 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $71.19 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $51.08 | 2024 | Winrevair |
| United Therapeutics Corporation | $49.23 | 2025 | Tyvaso |
| Pbg Puerto Rico LLC | $18.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glorimar Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.